114 related articles for article (PubMed ID: 24301955)
1. Case report: A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia.
Coutinho DF; Diniz C; Filgueiras RL; Baptista RL; Ayres-Silva JP; Monte-Mór BC; Bonamino MH; Zalcberg IR
Genet Mol Res; 2013 Nov; 12(4):5858-62. PubMed ID: 24301955
[TBL] [Abstract][Full Text] [Related]
2. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
Mohamedali AM; Smith AE; Gaken J; Lea NC; Mian SA; Westwood NB; Strupp C; Gattermann N; Germing U; Mufti GJ
J Clin Oncol; 2009 Aug; 27(24):4002-6. PubMed ID: 19528370
[TBL] [Abstract][Full Text] [Related]
3. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
[TBL] [Abstract][Full Text] [Related]
4. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
[No Abstract] [Full Text] [Related]
6. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
7. Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
9. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.
Hellström-Lindberg E
Blood Rev; 2010 Mar; 24(2):83-90. PubMed ID: 20171768
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
[TBL] [Abstract][Full Text] [Related]
11. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes.
Hansen JW; Westman MK; Sjö LD; Saft L; Kristensen LS; Ørskov AD; Treppendahl M; Andersen MK; Grønbaek K
Am J Hematol; 2016 Dec; 91(12):1234-1238. PubMed ID: 27717004
[TBL] [Abstract][Full Text] [Related]
12. TET2 mutations in myelodysplasia and myeloid malignancies.
Mullighan CG
Nat Genet; 2009 Jul; 41(7):766-7. PubMed ID: 19557078
[TBL] [Abstract][Full Text] [Related]
13. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
[TBL] [Abstract][Full Text] [Related]
14. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
Kosmider O; Gelsi-Boyer V; Cheok M; Grabar S; Della-Valle V; Picard F; Viguié F; Quesnel B; Beyne-Rauzy O; Solary E; Vey N; Hunault-Berger M; Fenaux P; Mansat-De Mas V; Delabesse E; Guardiola P; Lacombe C; Vainchenker W; Preudhomme C; Dreyfus F; Bernard OA; Birnbaum D; Fontenay M;
Blood; 2009 Oct; 114(15):3285-91. PubMed ID: 19666869
[TBL] [Abstract][Full Text] [Related]
15. 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.
Gackowski D; Gawronski M; Kerr C; Radivoyevitch T; Zarakowska E; Starczak M; Abakir A; Ruzov A; Maciejewski JP; Olinski R
Haematologica; 2020 May; 105(5):e213-e215. PubMed ID: 31488558
[No Abstract] [Full Text] [Related]
16. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
17. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
Jain P; Tang G; Konoplev SN; Kanagal-Shamanna R; Wang SA; Pemmaraju N; Daver N; Estrov Z
Am J Hematol; 2016 Mar; 91(3):354-5. PubMed ID: 26437693
[No Abstract] [Full Text] [Related]
18. [Mutation of tet2 gene and malignant blood disease].
Qian XF; Shen YF; Zhang SJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
[TBL] [Abstract][Full Text] [Related]
19. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
20. Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome.
Dambruoso I; Boni M; Rossi M; Zappasodi P; Calvello C; Zappatore R; Cavigliano PM; Giardini I; Rocca B; Caresana M; Astori C; Cazzola M; Castagnola C; Bernasconi P
Cancer Genet; 2012 Jun; 205(6):285-94. PubMed ID: 22749034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
